Vicor Technologies, Inc. (OTCBB: VCRT) is a bio-technology company focused on the development and commercialization of innovative, non-invasive medical diagnostics using its patented, proprietary PD2i nonlinear algorithm and software to stratify patients at risk of sudden cardiac death or autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.
Diagnostics that enable inexpensive, accurate, and early identification of disease states in at-risk populations prior to costly treatments for advanced disease or inaccurate identification are garnering increased attention in the current healthcare debate. These populations are significant:
* 12 million at-risk cardiac patients * 23.6 million diabetics * 38 million trauma incidents
Vicor's diagnostics are being developed to address those needs easily, accurately, and inexpensively. Vicor’s PD2i Analyzer™ has already received FDA 510(k) marketing clearance to measure heart rate variability; the use of which is physician determined. (Physicians who have purchased the PD2i Analyzer™ are largely using it to test their diabetic patients for autonomic nervous system (ANS) dysfunction, also known as diabetic autonomic neuropathy or DAN.) Current procedural terminology (CPT) codes currently exist, enabling physicians using the PD2i Analyzer™ to measure HRV to be reimbursed by insurance carriers, and creating a recurring source of revenue from test analysis for Vicor.